395 related articles for article (PubMed ID: 33357483)
21. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.
Biondi A; Schrappe M; De Lorenzo P; Castor A; Lucchini G; Gandemer V; Pieters R; Stary J; Escherich G; Campbell M; Li CK; Vora A; Aricò M; Röttgers S; Saha V; Valsecchi MG
Lancet Oncol; 2012 Sep; 13(9):936-45. PubMed ID: 22898679
[TBL] [Abstract][Full Text] [Related]
22. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
23. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO).
Candoni A; Rambaldi A; Fanin R; Velardi A; Arcese W; Ciceri F; Lazzarotto D; Lussana F; Olivieri J; Grillo G; Parma M; Bruno B; Sora F; Bernasconi P; Saccardi R; Foà R; Sessa M; Bresciani P; Giglio F; Picardi A; Busca A; Sica S; Perruccio K; Zucchetti E; Diral E; Iori AP; Colombo AA; Tringali S; Santarone S; Irrera G; Mancini S; Zallio F; Malagola M; Albano F; Carella AM; Olivieri A; Tecchio C; Dominietto A; Vacca A; Sorasio R; Orciuolo E; Risitano AM; Leotta S; Cortelezzi A; Mammoliti S; Oldani E; Bonifazi F;
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2388-2397. PubMed ID: 31400502
[TBL] [Abstract][Full Text] [Related]
24. BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.
Boer JM; den Boer ML
Eur J Cancer; 2017 Sep; 82():203-218. PubMed ID: 28709134
[TBL] [Abstract][Full Text] [Related]
25. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.
Den Boer ML; van Slegtenhorst M; De Menezes RX; Cheok MH; Buijs-Gladdines JG; Peters ST; Van Zutven LJ; Beverloo HB; Van der Spek PJ; Escherich G; Horstmann MA; Janka-Schaub GE; Kamps WA; Evans WE; Pieters R
Lancet Oncol; 2009 Feb; 10(2):125-34. PubMed ID: 19138562
[TBL] [Abstract][Full Text] [Related]
26. Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions.
Venn NC; Huang L; Hovorková L; Muskovic W; Wong M; Law T; Heatley SL; Khaw SL; Revesz T; Dalla Pozza L; Shaw PJ; Fraser C; Moore AS; Cross S; Bendak K; Norris MD; Henderson MJ; White DL; Cowley MJ; Trahair TN; Zuna J; Sutton R
Br J Cancer; 2022 Sep; 127(5):908-915. PubMed ID: 35650277
[TBL] [Abstract][Full Text] [Related]
27. Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach - a population-based study.
Norvilas R; Dirse V; Semaskeviciene R; Mickeviciute O; Gineikiene E; Stoskus M; Vaitkeviciene G; Rascon J; Griskevicius L
BMC Cancer; 2021 Mar; 21(1):326. PubMed ID: 33781217
[TBL] [Abstract][Full Text] [Related]
28. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
Schwab C; Ryan SL; Chilton L; Elliott A; Murray J; Richardson S; Wragg C; Moppett J; Cummins M; Tunstall O; Parker CA; Saha V; Goulden N; Vora A; Moorman AV; Harrison CJ
Blood; 2016 May; 127(18):2214-8. PubMed ID: 26872634
[TBL] [Abstract][Full Text] [Related]
29. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA
Br J Haematol; 2015 Feb; 168(3):395-404. PubMed ID: 25312094
[TBL] [Abstract][Full Text] [Related]
30. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
31. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
32. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
Roberts KG; Pei D; Campana D; Payne-Turner D; Li Y; Cheng C; Sandlund JT; Jeha S; Easton J; Becksfort J; Zhang J; Coustan-Smith E; Raimondi SC; Leung WH; Relling MV; Evans WE; Downing JR; Mullighan CG; Pui CH
J Clin Oncol; 2014 Sep; 32(27):3012-20. PubMed ID: 25049327
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
[TBL] [Abstract][Full Text] [Related]
35. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
Olsson L; Ivanov Öfverholm I; Norén-Nyström U; Zachariadis V; Nordlund J; Sjögren H; Golovleva I; Nordgren A; Paulsson K; Heyman M; Barbany G; Johansson B
Br J Haematol; 2015 Sep; 170(6):847-58. PubMed ID: 26018335
[TBL] [Abstract][Full Text] [Related]
36. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia.
Lovisa F; Zecca M; Rossi B; Campeggio M; Magrin E; Giarin E; Buldini B; Songia S; Cazzaniga G; Mina T; Acquafredda G; Quarello P; Locatelli F; Fagioli F; Basso G
Br J Haematol; 2018 Mar; 180(5):680-693. PubMed ID: 29359790
[TBL] [Abstract][Full Text] [Related]
37. High frequency and poor prognosis of late childhood BCR-ABL-positive and MLL-AF4-positive ALL define the need for advanced molecular diagnostics and improved therapeutic strategies in pediatric B-ALL in Pakistan.
Iqbal Z; Akhtar T; Awan T; Aleem A; Sabir N; Rasool M; Absar M; Akram AM; Shammas MA; Shah IH; Khalid M; Taj AS; Jameel A; Alanazi A; Gill AT; Hashmi JA; Hussain A; Sabar MF; Khalid AM; Qazi MH; Karim S; Siddiqi MH; Mahmood A; Iqbal M; Saeed A; Irfan MI
Mol Diagn Ther; 2015 Oct; 19(5):277-87. PubMed ID: 26266519
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic haematopoietic stem cell transplantation for infant acute lymphoblastic leukaemia with KMT2A (MLL) rearrangements: a retrospective study from the paediatric acute lymphoblastic leukaemia working group of the Japan Society for Haematopoietic Cell Transplantation.
Kato M; Hasegawa D; Koh K; Kato K; Takita J; Inagaki J; Yabe H; Goto H; Adachi S; Hayakawa A; Takeshita Y; Sawada A; Atsuta Y; Kato K
Br J Haematol; 2015 Feb; 168(4):564-70. PubMed ID: 25302748
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.
Moorman AV; Barretta E; Butler ER; Ward EJ; Twentyman K; Kirkwood AA; Enshaei A; Schwab C; Creasey T; Leongamornlert D; Papaemmanuil E; Patrick P; Clifton-Hadley L; Patel B; Menne T; McMillan AK; Harrison CJ; Rowntree CJ; Marks DI; Fielding AK
Leukemia; 2022 Mar; 36(3):625-636. PubMed ID: 34657128
[TBL] [Abstract][Full Text] [Related]
40. Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification.
Schwab CJ; Murdy D; Butler E; Enshaei A; Winterman E; Cranston RE; Ryan S; Barretta E; Hawking Z; Murray J; Antony G; Vora A; Moorman AV; Harrison CJ
Br J Haematol; 2022 Feb; 196(3):753-763. PubMed ID: 34676543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
